PROTAC targeted protein degraders: the past is prologue
2022 · Nature Reviews Drug Discovery · 2,731 citations
https://doi.org/10.1038/s41573-021-00371-6
M
Miklós Békés
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
47
Papers
4.8K
Citations
20
h-index
22
i10-index
Miklós Békés is an academic researcher from Arvinas (United States). The author has contributed to research in topics: Ubiquitin and proteasome pathways & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 20, co-authored 40 publications.
ORCID: 0000-0001-8423-9235Papers by this author
worksOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
2024 · Clinical Cancer Research · 132 citations
https://doi.org/10.1158/1078-0432.ccr-23-3465
A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
2021 · Cell Reports · 49 citations
https://doi.org/10.1016/j.celrep.2021.109754
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat